Prahlad Singh, PerkinElmer CEO

Shelling out $5B+, PerkinElmer pays the big bucks for an­ti­body and reagent play­er

PerkinElmer has been busy on the ac­qui­si­tion front through­out the Covid-19 pan­dem­ic, and on Mon­day, the Mass­a­chu­setts-based di­ag­nos­tics and life sci­ences com­pa­ny added the biggest feath­er to its cap.

PerkinElmer will ac­quire an­ti­body and reagents provider Bi­oLe­gend for near­ly $5.25 bil­lion, the en­ti­ties an­nounced Mon­day morn­ing. The deal is PerkinElmer’s third ac­qui­si­tion since No­vem­ber 2020 as it kicked de­vel­op­ment of Covid-19 test­ing in­to high gear, as well as the com­pa­ny’s biggest buy­out ever.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.